Treatment of a patient with EGFR L747S and L858R double-mutated lung adenocarinoma

Published on Apr. 07, 2023Total Views: 1773 times Total Downloads: 680 times Download Mobile

Author: Teng-Fei WANG Wen OUYANG Jun-Hong ZHANG Gong ZHANG  Cong-Hua XIE

Affiliation: Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China

Keywords: EGFR L747S mutation Lung adenocarcinoma Osimertinib Pem-brolizumab

DOI: 10.12173/j.issn.1004-4337.202302078

Reference: Wang TF, Ouyang W, Zhang JH, Zhang G, Xie CH. Treatment of a patient with EGFR L747S and L858R double-mutated lung adenocarcinoma[J]. Journal of Mathematical Medicine, 2023, 36(3): 230-235. DOI: 10.12173/j.issn.1004-4337.202302078[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Exon 19 deletion mutation and exon 21 L858R mutation are the most prevalent epidermal growth factor receptor (EGFR) mutations that are responsive to EGFR tyrosine kinase in-hibitors (EGFR-TKIs). However, the efficacy of EGFR-TKIs against rare EGFR mutations is debatable. Many patients will eventually develop resistance to EGFR-TKIs over time. Furthermore, there is still no standard protocol for patients developing resistance to Osimertinib, particularly those with rare or complex mutations. Here, we present a lung adenocarcinoma patient with EGFR L747S and L858R double mutations, who responded to Pembrolizumab plus chemotherapy after developing Osimertinib resistance, with a thirteen-month response duration. This is the first report of the efficacy of Pem-brolizumab plus chemotherapy after Osimertinib resistance on a patient harboring EGFR L747S and L858R double mutations. Our case can serve as a therapy recommendation for patients with comparable rare mutations.

Full-text

Please download the PDF version to read the full text: download

References

1.Hsu WH, Yang JC, Mok TS, et al. Overview of current systemic management of EGFR-mutant NSCLC[J]. Ann Oncol, 2018, 29: i3-i9. DOI: 10.1093/annonc/mdx702.

2.Andrews Wright NM, Goss GD. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer[J]. Translational Lung Cancer Research, 2019, 8(Suppl 3): S247-S264. DOI: 10.21037/tlcr.2019.06.01.

3.Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J]. Clin Cancer Res, 2013, 19(8): 2240-2247. DOI: 10.1158/1078-0432.CCR-12-2246.

4.Chiba M, Togashi Y, Bannno E, et al. Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A[J]. BMC Cancer, 2017, 17(1): 281. DOI: 10.1186/s12885-017-3263-z.

5.Ettinger DS, Wood DE, Aisner D, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(5): 497-530. DOI: 10.6004/jnccn.2022.0025.

6.Costa DB, Halmos B, Kumar A, et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations[J]. PLoS Med, 2007, 4(10): 1669-1679. DOI: 10.1371/journal.pmed.0040315.

7.Grolleau E, Haddad V, Boissière L, et al. Clinical efficacy of osimertinib in a patient presenting a double EGFR L747S and G719C mutation[J]. J Thorac Oncol, 2019, 14(7): e151-e153. DOI: 10.1016/j.jtho.2019.02.034.

8.He Q, Shi X, Zhu H, et al. A case treated with crizotinib after secondary MET amplification of a double rare L747S and G719S EGFR mutation pulmonary sarcomatoid carcinoma[J]. Ann Oncol, 2020, 31(4): 544-546. DOI: 10.1016/j.annonc.2020.01.010.

9.Liang SK, Ko JC, Yang JC, et al. Afatinib is effective in the treatment of lung adenocarcinoma with un-common EGFR p.L747P and p.L747S mutations[J]. Lung Cancer, 2019, 133: 103-109. DOI: 10.1016/j.lungcan.2019.05.019.

10.Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer[J]. Clin Cancer Res, 2019, 25(22): 6644-6652. DOI: 10.1158/1078-0432.CCR-19-1126.

11.Girard N. New strategies and novel combinations in EGFR TKI-resistant non-small cell lung cancer[J]. Curr Treat Options Oncol, 2022, 23(11): 1626-1644. DOI: 10.1007/s11864-022-01022-7.

12.Huang J, Wang Y, Zhai Y, et al. Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): a case report[J]. Thoracic Cancer, 2018, 9(6): 745-749. DOI: 10.1111/1759-7714.12637.

13.Huang X, Yang Y, Wang P, et al. A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: a case report[J]. Lung Cancer, 2020, 150: 9-11. DOI: 10.1016/j.lungcan.2020.09.017.

14.To KKW, Fong W, Cho WCS. Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies[J]. Front Oncol, 2021, 11: 635007. DOI: 10.3389/fonc.2021.635007.

15.Johnson M, Garassino MC, Mok T, et al. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies[J]. Lung Cancer, 2022, 170: 41-51. DOI: 10.1016/j.lungcan.2022.05.011.

16.Wu SG, Shih JY. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer, 2018, 17(1): 38. DOI: 10.1186/s12943-018-0777-1.

17.Biton J, Mansuet-Lupo A, Pécuchet N, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti–PD-1 in lung adenocarcinoma[J]. Clin Cancer Res, 2018, 24(22): 5710-5723. DOI: 10.1158/1078-0432.CCR-18-0163.

18.Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res, 2017, 23(12): 3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554.